Mr. Glenn Schulman reports
AURINIA CLOSES AT-THE-MARKET FACILITY
Further to its open market sale agreement with
Jefferies LLC previously disclosed on Nov. 30, 2018, in relation to
at-the-market (ATM) offerings of common shares in the capital of the
company, Aurinia Pharmaceuticals Inc. has completed the sale of 4,608,409 common shares
at a weighted average price of $6.55 (U.S.) for aggregate gross proceeds of
approximately $30-million (U.S.). No further sales will be conducted pursuant
to the ATM.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals is a clinical late-stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations impacted by serious
diseases with a high unmet medical need.
© 2024 Canjex Publishing Ltd. All rights reserved.